All In Biotech

NDA 009053 · Stason Pharms

Purinethol

Mercaptopurine · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jul 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1953

Sep 11, 1953

Approved uses

1

Original approval plus efficacy supplements

Registered trials

396

144 Phase 3, 58 recruiting

FAERS reports

17,433

15,076 serious, 1,975 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 30, 2026.

Mercaptopurine tablets is a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. (1.1) 1.1 Acute Lymphoblastic Leukemia Mercaptopurine tablets are indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Mechanism: Mercaptopurine is a purine analog that undergoes intracellular transport and activation to form metabolites including thioguanine nucleotides (TGNs). Incorporation of TGNs into DNA or RNA results in cell-cycle arrest and cell death. TGNs and other mercaptopurine metabolites are also inhibitors of de novo purine synthesis and purine nucleotide interconversions. Mercaptopurine was cytotoxic to proliferating cancer cells in vitro and had antitumor activity in mouse tumor models. It is not known which of the biochemical effects of mercaptopurine and its metabolites are directly or predominantly...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 11, 1953 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • PURINETHOL · MERCAPTOPURINE 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mercaptopurine" as an intervention, any sponsor and status, largest first.

All 396 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia1,932
  • pyrexia1,192
  • off label use1,150
  • drug ineffective1,108
  • nausea800
  • vomiting761
  • diarrhoea705
  • abdominal pain703
  • neutropenia612
  • headache603
  • fatigue556
  • pneumonia529

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004192
2005151
2006163
2007223
2008272
2009478
2010554
2011643
2012830
2013465
2014765
2015780
2016865
20171,062
20181,186
20191,229
20201,146
20211,273
20221,402
20231,221
20241,135
2025831
2026567

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 476 on PubMed

Sponsor: Stason Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.